SCYNEXIS Inc (SCYX) - Company Sales

The management stability of SCYNEXIS, Inc. (SCYX) is ensured by a strategic alliance with GSK and transparent license payments. The company's execution history clearly demonstrates sales dynamics, where the value of 0.02 represents the most recent figure. The uniqueness of its antifungal developments and patent protection guarantee financial strength, while independence from macroeconomic fluctuations makes the asset a reliable defensive tool during recessionary periods.

SCYX: SCYNEXIS Revenue and Sales Volume 07/04/2022 - 11/13/2026

Analytical breakdowns for SCYNEXIS, Inc.

- market price and analyst price targets:

Market Price Scynexis|SCYX - Analyst Consensus Forecast

- market capitalization indicators:

Market Valuation SCYNEXIS, Inc.|SCYX - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Price of a Share SCYNEXIS|SCYX - Book Capitalization|Market Capitalization to Book Value scynexis.com|SCYX - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples information:

SCYX - Net Income|Expected Net Profit SCYNEXIS, Inc.|SCYX - Price to Earnings Ratio|Price to Future Earnings Ratio Scynexis|SCYX - PEG Multiple|Company Value to EBITDA SCYNEXIS, Inc.|SCYX - Operating profit before deduction of amortization|Earnings per share for the last 12 months SCYNEXIS|SCYX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months scynexis.com|SCYX - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year SCYNEXIS, Inc.

- company sales and revenue statistics:

SCYX - Company Sales|Company Future Revenue Scynexis|SCYX - P/S Multiple|Market Cap to Expected Sales Ratio SCYNEXIS, Inc.

Comprehensive company analysis:SCYNEXIS, Inc.

The development of unique antifungal agents for the hospital and retail sectors generates the primary cash flow for SCYNEXIS, Inc. (SCYX). This indicator aggregates actual proceeds from drug sales, converting discrete payments into continuous revenue dynamics. An analysis of the company's current sales allows for an assessment of the pace of commercial expansion and the stability of the issuer's market positions. Steady growth in this metric confirms the effectiveness of business diversification and enhances the investment attractiveness of the capital.

Analysis of competing companies